In the meta-analysis of these nine studies, including a total of 1070 lesions [19,20,23,24,25,30,43,46,47], the pooled difference in proportions of type III curves (wash-out) between and HER2-positive and HER2-negative cancers for all included tumours was 0.08, (95% CI = [0.01, 0.14]), heterogeneity τ2 = 0.00, I2 = 0%, test for overall effect Z = 2.40 (p = 0.02) (Figure 2b). The gene discussed is ERBB2; the disease is cancer.